Anti-VEGF Receptor 3 antibody (ab27278)
Key features and details
- Rabbit polyclonal to VEGF Receptor 3
- Suitable for: ICC/IF, WB, IHC-P, IHC - Wholemount
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-VEGF Receptor 3 antibody
See all VEGF Receptor 3 primary antibodies -
Description
Rabbit polyclonal to VEGF Receptor 3 -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, WB, IHC-P, IHC - Wholemountmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human VEGF Receptor 3 aa 1250-1350. The exact sequence is proprietary.
Database link: P35916 -
Positive control
- IHC-P: Human placenta tissue. ICC/IF: HeLa cells. WB: Hey cell lysate.
-
General notes
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab27278 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
Use a concentration of 1 µg/ml.
|
|
WB | (1) |
Use at an assay dependent concentration. Predicted molecular weight: 146 kDa.
|
IHC-P | (5) |
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
IHC - Wholemount | (1) |
Use at an assay dependent concentration.
|
Notes |
---|
ICC/IF
Use a concentration of 1 µg/ml. |
WB
Use at an assay dependent concentration. Predicted molecular weight: 146 kDa. |
IHC-P
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
IHC - Wholemount
Use at an assay dependent concentration. |
Target
-
Function
Receptor for VEGFC. Has a tyrosine-protein kinase activity. -
Tissue specificity
Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain. -
Involvement in disease
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 2324 Human
- Entrez Gene: 14257 Mouse
- Entrez Gene: 114110 Rat
- Omim: 136352 Human
- SwissProt: P35916 Human
- SwissProt: P35917 Mouse
- SwissProt: Q91ZT1 Rat
- Unigene: 646917 Human
see all -
Alternative names
- EC 2.7.10.1 antibody
- flt 4 antibody
- FLT-4 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 3 antibody (ab27278)Ab27278 at a dilution of 1/100, staining formalin fixed paraffin embedded Flt4 in human placenta by Immunohistochemistry.
-
ICC/IF image of ab27278 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab27278, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
-
Anti-VEGF Receptor 3 antibody (ab27278) at 1/50 dilution
Predicted band size: 146 kDa
Observed band size: 170,200 kDa why is the actual band size different from the predicted?
Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1:50 for 2 hours at room tepterature Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1:50 for 2 hours at room temperature. The protein is heavily glycosylated and this might explain the increase in MW above the predcted MW as well as the multiple bands.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (44)
ab27278 has been referenced in 44 publications.
- Kim BH et al. Restoration of Homeostasis in the Tracheal Mucosa After Thyroid Surgery in a Rat Model. In Vivo 36:161-169 (2022). PubMed: 34972711
- Bae JH et al. Gatekeeping role of Nf2/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization. Sci Adv 8:eabn2611 (2022). PubMed: 35687678
- Dai XW et al. lncRNA-MIAT facilitates the differentiation of adipose-derived mesenchymal stem cells into lymphatic endothelial cells via the miR-495/Prox1 axis. Mol Med Rep 23:N/A (2021). PubMed: 33760182
- Lin QY et al. VEGF-C/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis. Clin Transl Med 11:e374 (2021). PubMed: 33783987
- Li F et al. Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer. Clin Cancer Res 26:1318-1326 (2020). PubMed: 31843751